Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Interferon Alfa · 2 trials · 2 indications
Progression-free survival (PFS) = time from randomization to first documentation of objective tumor progression or to death due to any cause, whichever occured first. If tumor progression data included more than 1 date, the first date was used. PFS = first event date minus the date of randomization + 1. On study included treatment plus 28-day follow-up periods.
Progression-free survival = time from randomization to first documentation of objective tumor progression or to death due to any cause, whichever occured first. PFS = first event date minus the date of randomization + 1). On study included treatment plus 28-day follow-up periods.
Overall survival is the duration from randomization to death. For participants who are alive, overall survival is censored at the last contact.
| Arm | Type | Description |
|---|---|---|
| 2 | ACTIVE_COMPARATOR | - |
| 1 | EXPERIMENTAL | - |
| A | ACTIVE_COMPARATOR | - |
| B | EXPERIMENTAL | - |
| C | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Interferon-alfa | DRUG | 3 MIU first week, 6 MIU second week, and 9 MIU thereafter three times a week (non-consecutive days) until progression or unacceptable toxicity |
| SU011248 | DRUG | 50 mg orally daily for 4 weeks and 2 weeks off treatment until progression or unacceptable toxicity |
| Interferon Alfa | DRUG | Interferon alfa (Roferon) 3 MU given Sub Cutaneously three time /week for the first week, 9 MU given Sub Cutaneously three time /week for the second week, 18 MU given Sub Cutaneously three time /week thereafter. |
| CCI-779 | DRUG | 25 mg of CCI-779 given Intra Venously once per week |
| Interferon Alfa and CCI-779 | DRUG | 15 mg of CCI-779 given Intra Venously once per week; 6 MU of IFN alfa (Roferon) given Sub Cutaneously three time /week |
Inclusion Criteria: * Histologically confirmed renal cell carcinoma of clear cell histology with metastases * Evidence of measurable disease by radiographic technique * Eastern Cooperative Oncology Group \[ECOG\] performance status of 0 or 1 Exclusion Criteria: * Prior systemic (including adjuvan...
Interferon Alfa is used for the treatment of Carcinoma, Renal Cell, also known as renal cell carcinoma. It has been evaluated in Phase 3 clinical trials as a therapy for this condition, including in patients with metastatic renal cell carcinoma.
Interferon Alfa is developed by Pfizer, Inc., a company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is being studied for use in oncology, specifically for renal cell carcinoma.
Interferon Alfa is in Phase 3 clinical development. It has completed two Phase 3 trials, and it remains an investigational drug, meaning it is still in clinical development and has not been approved for use.
Interferon Alfa has been studied in two completed Phase 3 trials. One trial, NCT00065468, evaluated Interferon and CCI-779 in advanced renal cell carcinoma with 626 participants. Another trial, NCT00083889, compared SU011248 versus Interferon-Alfa as first-line therapy for metastatic renal cell carcinoma with 750 participants.
Interferon Alfa is a distinct drug entity. It has been compared against other agents in clinical trials, such as CCI-779 and SU011248, but it is not the same as those drugs. No alternative names for Interferon Alfa have been established.